Y. M D Lo
University of Oxford
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Y. M D Lo.
The New England Journal of Medicine | 1998
Y. M D Lo; N. M. Hjelm; C. Fidler; Ian L. Sargent; Michael F. Murphy; P. F. Chamberlain; P. M. K. Poon; C. W. G. Redman; James S. Wainscoat
BACKGROUND The ability to determine fetal RhD Status noninvasively is useful in the treatment of RhD-sensitized pregnant women whose partners are heterozygous for the RhD gene. The recent demonstration of fetal DNA in maternal plasma raises the possibility that fetal RhD genotyping may be possible with the use of maternal plasma. METHODS We studied 57 RhD-negative pregnant women and their singleton fetuses. DNA extracted from maternal plasma was analyzed for the RhD gene with a fluorescence-based polymerase-chain-reaction (PCR) test sensitive enough to detect the RhD gene in a single cell. Fetal RhD status was determined directly by serologic analysis of cord blood or PCR analysis of amniotic fluid. RESULTS Among the 57 RhD-negative women, 12 were in their first trimester of pregnancy, 30 were in their second trimester, and 15 were in their third trimester. Thirty-nine fetuses were RhD-positive, and 18 were RhD-negative. In the samples obtained from women in their second or third trimester of pregnancy, the results of RhD PCR analysis of maternal plasma DNA were completely concordant with the results of serologic analysis. Among the maternal plasma samples collected in the first trimester, 2 contained no RhD DNA, but the fetuses were RhD-positive; the results in the other 10 samples were concordant (7 were RhD-positive, and 3 RhD-negative). CONCLUSIONS Noninvasive fetal RhD genotyping can be performed rapidly and reliably with the use of maternal plasma beginning in the second trimester of pregnancy.
The Lancet | 1989
Y. M D Lo; James S. Wainscoat; MichaelD.G. Gillmer; P. Patel; Maurizio Sampietro; Kenneth A. Fleming
The polymerase chain reaction was used to amplify a Y-specific repeat sequence in peripheral blood DNA samples from 19 pregnant women who had a gestational age of 9 to 41 weeks. Y-specific sequences were amplified from all 12 women who bore a male fetus but in none of 7 women who bore a female fetus. With stringent precautions against contamination, this technique may assist prenatal diagnosis of sex-linked genetic disorders.
The Lancet | 1994
Y. M D Lo; James S. Wainscoat
The invention relates to a detection method performed on a maternal serum or plasma sample from a pregnant female, which method comprises detecting the presence of a nucleic acid of foetal origin in the sample. The invention enables non-invasive prenatal diagnosis including for example sex determination, blood typing and other genotyping, and detection of pre-eclampsia in the mother.
The Lancet | 1993
Y. M D Lo; P.J. Bowell; M. Selinger; I.Z. Mackenzie; P. Chamberlain; M.D.G. Gillmer; T.J. Littlewood; Kenneth A. Fleming; James S. Wainscoat
The Lancet | 1994
Y. M D Lo; A. L. Morey; James S. Wainscoat; Kenneth A. Fleming
Archive | 1990
Kenneth A. Fleming; James S. Wainscoat; P. Patel; Y. M D Lo
Archive | 1998
Y. M D Lo; James S. Wainscoat
The Lancet | 1990
Y. M D Lo; P. Patel; James S. Wainscoat; Kenneth A. Fleming
Archive | 1998
Y. M D Lo; James S. Wainscoat
The Lancet | 1994
Y. M D Lo; James S. Wainscoat; Kenneth A. Fleming